Botensilimab not checked
Agenus Inc. · AGEN1181 · Anti-CTLA-4
FollowEvery change as it happens, and a Monday email
Trials
5 active
9 in total · 5 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.”In the company’s words, NCT05608044 on ClinicalTrials.gov
- Tested for
- Metastatic Colorectal Cancer, Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer and 1 more
- Main trialPhase 2
- “This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.”In the company’s words, NCT05608044 on ClinicalTrials.gov
- Other names
- AGEN1181 · Anti-CTLA-4
Other drugs for Metastatic Colorectal Cancer
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up1
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Sep 2027 | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | |
| Phase 1Active, not recruiting | 13 Jan 2025 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | |
| Phase 2Completed | 5 Jan 2026 | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | |
| Phase 2Terminated | 27 Apr 2026 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | |
| Phase 1Completed | 22 Feb 2024 | Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer | |
| Phase 1Completed | 23 Dec 2024 | Study of AGEN1571 in Participants With Advanced Solid Tumors | |
| Phase 2Authorised | not given | WINDOW-OF-OPPORTUNITY UMBRELLA PLATFORM TRIAL OF SHORT-COURSE PRE-OPERATIVE OR NEOADJUVANT TARGETED TREATMENT IN PATIENTS WITH MOLECULARLY SELECTED AND RESECTABLE PRIMARY COLORECTAL CANCER: THE UNICORN STUDY | |
| Phase 2Authorised | not given | Pan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS) | |
| Phase 3Authorised | not given | CIME - Combination of Immune checkpoint in locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas : A multicenter, randomised, comparative, open-label Phase III aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab + balstilimab) versus the standard of care (FOLFOX/XELOX + nivolumab) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026